Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Feature|Videos|January 8, 2024
AstraZeneca Vice President, Head of Breast Cancer Franchise, Discusses Impact of Truqap Approval
Author(s)Don Tracy, Associate Editor
In an interview with Pharmaceutical Executive associate editor Don Tracy, Ashley Gaines, VP, head of breast cancer franchise, discusses newly approved Truqap.
Advertisement
Advertisement
Related to this article
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Shionogi’s Dr. Draica on why COVID-19 still matters — and why the window between exposure and symptoms is where XOCOVA can intervene.
Brox.AI’s Hamish Brocklebank on why it retired “digital twin” for “digital clone” — and why the distinction matters for pharma research accuracy.
Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
How Preventative Medications May Impact the Lingering Impact of COVID-19
4
Rebuilding Clinical Data Workflows for the AI Era
5